Clinical Trial Update: Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of bortezomib in patients with low or intermediate-1 myelodysplastic syndrome with p65 activation has completed, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-04-23